The Generational Leap: Dual vs Triple Agonism
The study of incretin mimetic peptides has evolved from single-receptor GLP-1 targeting to multi-receptor synergies.
This monograph examines the two leading compounds in metabolic biology: Tirzepatide and Retatrutide.
Pharmacological Comparison
- Tirzepatide: Dual GIP/GLP-1 receptor co-agonist (4813.5 Da). Synergistic insulinotropic and glucagonostatic actions with minimal nausea.
- Retatrutide: Triple GIP/GLP-1/GCGR receptor agonist (4731.3 Da). Adds glucagon receptor recruitment to stimulate hepatic lipid oxidation and thermogenic expenditure.
